MX337862B - Composiciones y métodos para el tratamiento de la esclerosis multiple. - Google Patents
Composiciones y métodos para el tratamiento de la esclerosis multiple.Info
- Publication number
- MX337862B MX337862B MX2010011846A MX2010011846A MX337862B MX 337862 B MX337862 B MX 337862B MX 2010011846 A MX2010011846 A MX 2010011846A MX 2010011846 A MX2010011846 A MX 2010011846A MX 337862 B MX337862 B MX 337862B
- Authority
- MX
- Mexico
- Prior art keywords
- fluids
- electrokinetically
- altered
- membrane
- therapeutic compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 201000006417 multiple sclerosis Diseases 0.000 title 1
- 239000012530 fluid Substances 0.000 abstract 6
- 239000012528 membrane Substances 0.000 abstract 4
- 230000001413 cellular effect Effects 0.000 abstract 3
- 230000001225 therapeutic effect Effects 0.000 abstract 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract 2
- 239000007789 gas Substances 0.000 abstract 2
- 108010052285 Membrane Proteins Proteins 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 210000003976 gap junction Anatomy 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000028709 inflammatory response Effects 0.000 abstract 1
- 210000004692 intercellular junction Anatomy 0.000 abstract 1
- 230000031146 intracellular signal transduction Effects 0.000 abstract 1
- 102000006240 membrane receptors Human genes 0.000 abstract 1
- 108020004084 membrane receptors Proteins 0.000 abstract 1
- 239000002086 nanomaterial Substances 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 210000001578 tight junction Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4833208P | 2008-04-28 | 2008-04-28 | |
| US4834708P | 2008-04-28 | 2008-04-28 | |
| US12/256,774 US20090227018A1 (en) | 2007-10-25 | 2008-10-23 | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
| PCT/US2008/081021 WO2009055614A1 (en) | 2007-10-25 | 2008-10-23 | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
| US12/258,210 US20090274730A1 (en) | 2007-10-25 | 2008-10-24 | Compositions and methods for treating inflammation |
| PCT/US2008/081202 WO2009055729A1 (en) | 2007-10-25 | 2008-10-24 | Compositions and methods for treating inflammation |
| PCT/US2009/041852 WO2009134728A2 (en) | 2008-04-28 | 2009-04-27 | Compositions and methods for treating multiple sclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2010011846A MX2010011846A (es) | 2011-04-11 |
| MX337862B true MX337862B (es) | 2016-03-16 |
Family
ID=43352974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010011846A MX337862B (es) | 2008-04-28 | 2009-04-27 | Composiciones y métodos para el tratamiento de la esclerosis multiple. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2282719B1 (https=) |
| JP (2) | JP5539965B2 (https=) |
| CN (1) | CN102076326B (https=) |
| AU (1) | AU2009241365B2 (https=) |
| BR (1) | BRPI0911612A2 (https=) |
| CA (1) | CA2722658C (https=) |
| MX (1) | MX337862B (https=) |
| WO (1) | WO2009134728A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8597689B2 (en) | 2006-10-25 | 2013-12-03 | Revalesio Corporation | Methods of wound care and treatment |
| US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
| US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
| US8980325B2 (en) | 2008-05-01 | 2015-03-17 | Revalesio Corporation | Compositions and methods for treating digestive disorders |
| CA2741336A1 (en) * | 2008-10-22 | 2010-04-29 | Revalesio Corporation | Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions |
| US8815292B2 (en) | 2009-04-27 | 2014-08-26 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
| MX2012012634A (es) * | 2010-04-30 | 2013-02-26 | Revalesio Corp | Métodos y composiciones para proteger contra agentes neurotóxicos. |
| BR112012028540A2 (pt) * | 2010-05-07 | 2016-07-26 | Revalesio Corp | composições e métodos para melhorar desempenho fisiológico e tempo de recuperação |
| JP2013533320A (ja) * | 2010-08-12 | 2013-08-22 | レバレジオ コーポレイション | タウオパチーを治療するための組成物および方法 |
| US20120263764A1 (en) * | 2011-04-13 | 2012-10-18 | Revalesio Corporation | Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease |
| CN103505731A (zh) * | 2012-06-15 | 2014-01-15 | 中国药科大学 | 1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途 |
| US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
| KR20240025721A (ko) * | 2015-06-15 | 2024-02-27 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 노화와 연관된 질환을 치료하기 위한 방법 및 조성물 |
| EP3456815B1 (en) * | 2016-05-13 | 2024-07-03 | SIGMA TECHNOLOGY, Inc. | Aqueous solution capable of being administered to living body, and method for producing same |
| EP3843673B1 (en) * | 2018-08-31 | 2026-04-15 | Revalesio Corporation | An oxygenated fluid for use for the treatment of stroke |
| EP3991746A4 (en) * | 2019-06-26 | 2023-08-09 | Takeda Pharmaceutical Company Limited | TRANSFECTION METHOD |
| US11686208B2 (en) | 2020-02-06 | 2023-06-27 | Rolls-Royce Corporation | Abrasive coating for high-temperature mechanical systems |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1157720A (ja) * | 1996-11-07 | 1999-03-02 | Honda Motor Co Ltd | 電解機能水、その製造方法及び製造装置 |
| US6386751B1 (en) | 1997-10-24 | 2002-05-14 | Diffusion Dynamics, Inc. | Diffuser/emulsifier |
| US7654728B2 (en) * | 1997-10-24 | 2010-02-02 | Revalesio Corporation | System and method for therapeutic application of dissolved oxygen |
| US6426066B1 (en) * | 2000-01-12 | 2002-07-30 | California Pacific Labs, Inc. | Use of physiologically balanced, ionized, acidic solution in wound healing |
| PL365909A1 (en) | 2000-02-21 | 2005-01-10 | Astrazeneca Ab | Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases |
| EP1357920B1 (en) * | 2001-02-01 | 2007-09-05 | Hydron Technologies Inc. | Compositions and method of tissue superoxygenation |
| SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| US7396441B2 (en) * | 2002-02-22 | 2008-07-08 | Aqua Innovations, Inc. | Flow-through oxygenator |
| US20030232114A1 (en) * | 2002-06-13 | 2003-12-18 | Nikola Dekleva | Method for liquid enrichment with oxygen and applications of enriched liquids |
| AU2002321678A1 (en) * | 2002-09-09 | 2004-03-29 | Boros Béla | Oxygen-enriched water, treated within a magnetic field and heavy water |
| NZ543102A (en) | 2003-04-24 | 2008-12-24 | Incyte Corp | Aza spiro alkane derivatives as inhibitors of metalloproteases |
| JP4144669B2 (ja) * | 2004-03-05 | 2008-09-03 | 独立行政法人産業技術総合研究所 | ナノバブルの製造方法 |
| SE0400850D0 (sv) | 2004-03-30 | 2004-03-31 | Astrazeneca Ab | Novel Compounds |
| SE0403086D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
| CA2513350A1 (en) * | 2005-03-02 | 2006-09-02 | Sydney West Area Health Service | Treatment for multiple sclerosis |
| WO2007087637A2 (en) | 2006-01-26 | 2007-08-02 | Washington State University Research Foundation | Compositions and methods using matrix metalloproteinase (mmp) inhibitors for treating cognitive impairment characterized by persistent or sustained mmp expression and/or activity |
| WO2008018932A2 (en) * | 2006-05-01 | 2008-02-14 | The Board Of Trustees Of The Leland Stanford Junior University | Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury |
| JP5491185B2 (ja) * | 2006-10-25 | 2014-05-14 | リバルシオ コーポレイション | 傷のケアおよび処置の方法 |
| US8597689B2 (en) | 2006-10-25 | 2013-12-03 | Revalesio Corporation | Methods of wound care and treatment |
| AU2007308838B2 (en) | 2006-10-25 | 2014-03-13 | Revalesio Corporation | Mixing device and output fluids of same |
| EP2215260A4 (en) * | 2007-10-25 | 2011-04-20 | Revalesio Corp | COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION |
| CA2741336A1 (en) * | 2008-10-22 | 2010-04-29 | Revalesio Corporation | Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions |
-
2009
- 2009-04-27 AU AU2009241365A patent/AU2009241365B2/en active Active
- 2009-04-27 WO PCT/US2009/041852 patent/WO2009134728A2/en not_active Ceased
- 2009-04-27 JP JP2011507562A patent/JP5539965B2/ja active Active
- 2009-04-27 CN CN200980124930.5A patent/CN102076326B/zh active Active
- 2009-04-27 BR BRPI0911612A patent/BRPI0911612A2/pt not_active IP Right Cessation
- 2009-04-27 MX MX2010011846A patent/MX337862B/es active IP Right Grant
- 2009-04-27 EP EP09739530.5A patent/EP2282719B1/en active Active
- 2009-04-27 CA CA2722658A patent/CA2722658C/en active Active
-
2014
- 2014-05-01 JP JP2014094570A patent/JP5869612B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009241365A1 (en) | 2009-11-05 |
| JP2014169307A (ja) | 2014-09-18 |
| WO2009134728A2 (en) | 2009-11-05 |
| CA2722658C (en) | 2018-09-18 |
| CN102076326A (zh) | 2011-05-25 |
| MX2010011846A (es) | 2011-04-11 |
| CN102076326B (zh) | 2015-12-02 |
| EP2282719A2 (en) | 2011-02-16 |
| CA2722658A1 (en) | 2009-11-05 |
| JP5869612B2 (ja) | 2016-02-24 |
| WO2009134728A3 (en) | 2010-01-21 |
| JP5539965B2 (ja) | 2014-07-02 |
| AU2009241365B2 (en) | 2015-01-22 |
| EP2282719A4 (en) | 2011-11-09 |
| JP2011523627A (ja) | 2011-08-18 |
| BRPI0911612A2 (pt) | 2015-12-15 |
| EP2282719B1 (en) | 2018-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX337862B (es) | Composiciones y métodos para el tratamiento de la esclerosis multiple. | |
| MX2010004554A (es) | Composiciones y métodos para el tratamiento de inflamación. | |
| MX2013001636A (es) | Composiciones y metodos para el tratamiento de taupatias | |
| MX2011011333A (es) | Composiciones y metodos para tratar la resistencia a la insulina y la diabetes mellituscampo de la invencion. | |
| WO2009134929A3 (en) | Compositions and methods for treating digestive disorders | |
| ES2525238T3 (es) | Método para preparar emulsiones aceite-en-agua a partir de concentrados de geles autoemulsionantes | |
| AU2017241807A1 (en) | Medium, methods, cells and secreted factors for stem cell culture and therapy | |
| EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
| EA201190295A1 (ru) | Композиции для дермальной доставки, содержащие комплексы активного агента с частицами фосфата кальция, и способы их применения | |
| EA201071421A1 (ru) | Анти-flt3 антитела | |
| UY33802A (es) | Composiciones inmunógenas que comprenden un antígeno relacionado con M72 y que tienen una fuerza iónica baja | |
| EA201591427A1 (ru) | Соединения и их применения для модуляции гемоглобина | |
| HK1203528A1 (zh) | 包含igg2鉸鏈結構域的融合蛋白 | |
| EA201591426A1 (ru) | Соединения и их применения для модуляции гемоглобина | |
| GT200600112A (es) | Composiciiones de tigeciclina y metodos de preparacion | |
| MX2010008610A (es) | Emulsiones de aceite en agua estabilizadas que incluyen ingredientes activos agricolamente. | |
| MX2009013802A (es) | Polimeros emulsificantes y su uso. | |
| GB2520111A (en) | Methods for identifying modulators of Ras using nonlinear techniques | |
| EP4293116A3 (fr) | Fibrinogène liquide stable | |
| ATE524482T1 (de) | Ionische flüssigkeiten mit niedriger viskosität | |
| WO2006096835A3 (en) | Monitoring and manipulating cellular transmembrane potentials using nanostructures | |
| DE502005006577D1 (de) | 2-phenylethylbenzoat in kosmetischen öl-in-wasser-uv-lichtschutzemulsionen | |
| MX364915B (es) | Alimentador de químicos que incluye sistema de control de dilución. | |
| ATE483720T1 (de) | Verbindungen enthaltend organofluorochlorophosphatanionen | |
| FR2913887B1 (fr) | Composition sous forme de gel comprenant une substance odorante |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |